(Q36181295)

12 August 2017

Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders (English)

1 reference

12 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Heydorn WE

1

1 reference

PubMed ID

15992089

12 August 2017

language of work or name

English

0 references

publication date

1 April 1999

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

1 reference

12 August 2017

8

1 reference

12 August 2017

4

1 reference

12 August 2017

417-441

1 reference

Potent and long-lasting potentiation of two 5-hydroxytryptophan-induced effects in mice by three selective 5-HT uptake inhibitors

12 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Platelets as a model for neurones?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Development of β-adrenergic receptor subsensitivity by antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Effect of paroxetine, a selective 5-hydroxytryptamine uptake inhibitor, on beta-adrenoceptors in rat brain: autoradiographic and functional studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Subsensitivity of the norepinephrine receptor-coupled adenylate cyclase system in brain: Effects of Nisoxetine versus fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Enhancement of the responsiveness of cortical adrenergic receptors by chronic administration of the 5-hydroxytryptamine uptake inhibitor citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

A Review of the Cardiovascular Effects and Toxicity of Tricyclic Antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Cardiovascular effects of amitriptyline in anaesthetized dogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

The effect of tricyclic antidepressant drugs on the isolated perfused guinea-pig heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Clinical pharmacokinetics of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

The safety of concomitant use of sumatriptan and antidepressant treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Psychiatric reaction patterns to imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Importance of Psychiatric Diagnosis in Prediction of Clinical Drug Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Cognitive-behavioral psychotherapy for children and adolescents with OCD: a review and recommendations for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Paroxetine as a treatment for premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Paroxetine in the treatment of chronic daily headache.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

The pharmacokinetics of paroxetine in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.4.417

21 January 2018

Identifiers

DOI

10.1517/13543784.8.4.417

1 reference

12 August 2017

1 reference

PubMed ID

15992089